December 4, 2024

Higher Medicine Received a Letter of Intent (LOI) for the Seed Investment

From Montreal-based Desire Ventures, led by Dr. Assad Aslam, an acclaimed toxicologist and biotech investor, contingent upon a matching investor participating in the round. The proceed from the investment will fund IND-enabling pre-clinical research for the lead p38 inhibitor program for Friedreich's Ataxia.

Latest News

Our platform offers a variety of resources to keep you informed about our latest programs, key updates, achievements, and other significant developments in the field of healthcare and medicine.

Company Announcements
June 2, 2025

Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology

Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.

Read more
Company Announcements
April 25, 2025

Higher Medicine Selected for the Maryland TEDCO SBIR/STTR Proposal Lab 2025 Cohort

Funded by TEDCO and administered by the leading experts in the field, Proposal Lab supports companies in securing competitive and prestigious NSF and other grants to advance their R&D portfolios.

Read more
Company Announcements
April 25, 2025

Higher Medicine Selected for HiveBio Accelerator Cohort

HiveBio Accelerator program offers world-class training, mentorship, and support to help scale Higher Medicine and secure follow-on funding.

Read more